Table 5. Postnatal days of the first days of pharmacological treatment according to the different strategies of patent ductus arteriosus (PDA) treatment (days).
| PT group | PST group | ST group | Total | ||
|---|---|---|---|---|---|
| Ibuprofen* | Total | 0.7±1.3 | 3.2±4.3 | 5.6±7.2 | 4.6±6.4 |
| Oral | 0.0±0.0 | 3.7±5.1 | 7.4±9.0 | 5.7±7.7 | |
| IV | 0.7±1.3 | 2.6±2.8 | 4.8±6.1 | 4.0±5.5 | |
| Oral+IV | NA | 3.5±0.7 | 3.9±4.2 | 3.8±3.6 | |
| Indomethacin | 0.5±0.7 | 6.0 | 7.5±6.7 | 6.3±6.3 | |
| Others | 0.0 | NA | NA | 0.0 | |
| Total | 0.7±1.3 | 3.2±4.3 | 5.6±7.1 | 4.6±6.4 |
P<0.05 compared between oral, intravenous, and both oral and intravenous treatment of ibuprofen groups by one-way ANOVA test. PT, prophylactic treatment; PST, pre-symptomatic treatment; ST, symptomatic treatment; IV, intravenous; NA, not applicable; others, other medications used for treatment of preterm patent ductus arteriosus such as acetaminophen.